|Last Price||Today's Change||52-Week Range||Trading Volume|
|276.46||-2.78 (-1.00%)||265.00 - 480.18||1.6 million (Below Avg)|
Market data as of 2:26PM 10/08/15. Quotes are delayed by at least 15 min.
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS
10/08/2015 6:15 AM ET